EUVIMEDOtkrijte EUVIMED
CrossrefInformacijska kartica

Protective effects of ivermectin against ischemia-reperfusion-induced ovarian injury in rats

Nesrin Yilmaz, Seval Bulut, Seyma Ilayda Paltaci, Renad Mammadov, Cengiz Sarigul, Mustafa Ozkaraca, Behzat Tebrizi, Halis Suleyman

Frontiers in Pharmacology · 2026-11-04 · 17

DOI: 10.3389/fphar.2026.2003125 ↗
SažetakBibliografski podaci

Sažetak

Background Ovarian ischemia-reperfusion (I/R) injury induces severe tissue damage through oxidative stress and inflammation, and DNA damage. This study investigated the protective effects of short- and long-term ivermectin application against ovarian I/R injury in rats. Methods Twenty-four female Wistar albino rats were divided into four groups: sham operation (SOG), ovarian I/R (OIR), long-term ivermectin-applied I/R (LIOIR), and short-term ivermectin-applied I/R (SIOIR). Ovarian torsion was maintained for 3 h before detorsion. Ivermectin (2 mg/kg, orally) was administered for 3 or 6 days. Ovarian malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) were measured. Histopathological and immunohistochemical analyses of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were also performed. Results OIR increased MDA and reduced tGSH, SOD, and CAT. Three-day ivermectin pretreatment normalized oxidative stress marker levels to values comparable to those in the sham group, whereas six-day pretreatment provided no significant protection. Follicular degeneration was pronounced in OIR and LIOIR but markedly attenuated in SIOIR. Immunohistochemistry demonstrated preserved COX-1 expression and reduced COX-2 and 8-OHdG immunoreactivity following short-term ivermectin pretreatment. Conclusion Short-term ivermectin effectively protected ovarian tissue against experimental I/R injury by reducing oxidative stress, inflammation, and DNA damage, whereas prolonged pretreatment failed to provide comparable protection, supporting its therapeutic potential.

Znanje koje odgovara vašem radu.

Od besplatnog početka i osobnog pretraživanja literature do potpunog paketa Research Suite.

Prikaži tarife →

Jesu li uključeni svi cjeloviti tekstovi izdavača?

Ne. Bibliografski zapisi, sažeci i cjeloviti tekstovi različiti su sadržaji. Hoće li cjeloviti tekst biti dostupan ovisi o izvoru, Open Accessu i vašim postojećim licencama. Tarifa EUVIMED ne zamjenjuje dodatna izdavačka prava.

Prikaži tarife →